Fractyl Health, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0 | $93.0K | $120.0K |
| Cost of Revenue | $0 | $50.0K | $77.0K |
| Gross Profit | $0 | $43.0K | $43.0K |
| Gross Margin | — | 46.2% | 35.8% |
| Operating Expenses | |||
| Research & Development | $74.5M | $70.5M | $38.0M |
| SG&A Expense | $22.3M | $23.1M | $12.8M |
| Operating Income | $-96.8M | $-93.5M | $-50.8M |
| Operating Margin | — | -100,571.0% | -42,363.3% |
| Interest Expense | — | — | — |
| Pretax Income | — | — | — |
| Income Tax Expense | $0 | $0 | $0 |
| Net Income | $-141.0M | $-68.7M | $-77.1M |
| Net Margin | — | -73,864.5% | -64,242.5% |
| EPS (Basic) | $-1.86 | $-1.62 | $-2.16 |
| EPS (Diluted) | $-1.86 | $-1.62 | $-2.16 |
| Shares Outstanding (Basic) | 75.8M | 43.5M | 43.7M |
| Shares Outstanding (Diluted) | 75.8M | 43.5M | 43.7M |
| Dividends Per Share | — | — | — |